Common Contracts
4 similar Agreement and Plan of Merger contracts by Alexion Pharmaceuticals, Inc., Arqule Inc, Chembio Diagnostics, Inc., Portola Pharmaceuticals Inc
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • January 31st, 2023 • Chembio Diagnostics, Inc. • Pharmaceutical preparations • Nevada
This AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of January 31, 2023 (the “Agreement Date”) by and among Biosynex SA, a French société anonyme (“Parent”), Project Merci Merger Sub, Inc., a Nevada corporation and wholly-owned indirect Subsidiary of Parent (“Merger Sub”), and Chembio Diagnostics, Inc., a Nevada corporation (the “Company”). Each of Parent, Merger Sub and the Company are referred to herein as a “Party” and collectively as the “Parties”. Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER by and among PORTOLA PHARMACEUTICALS, INC., ALEXION PHARMACEUTICALS, INC. and Odyssey Merger Sub Inc. May 5, 2020Agreement and Plan of Merger • May 7th, 2020 • Portola Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER by and among PORTOLA PHARMACEUTICALS, INC., ALEXION PHARMACEUTICALS, INC. and Odyssey Merger Sub Inc. May 5, 2020Agreement and Plan of Merger • May 7th, 2020 • Alexion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 6, 2019 AMONG MERCK SHARP & DOHME CORP., ARGON MERGER SUB, INC. AND ARQULE, INC.Agreement and Plan of Merger • December 9th, 2019 • Arqule Inc • Pharmaceutical preparations • Delaware
Agreement and Plan of Merger (this “Agreement”), dated as of December 6, 2019, among MERCK SHARP & DOHME CORP., a New Jersey corporation (“Parent”), ARGON MERGER SUB, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and ARQULE, INC., a Delaware corporation (the “Company”).
